Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bharat Biotech
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.
China has cleared for sale the world's first inhaled vaccine for COVID-19, as China continues to face challenges to its strict "COVID Zero" policies, including a new extended lockdown in a major city, ahead of the upcoming high-stakes National Congress.
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
- Drug Discovery Tools
- Other Names / Subsidiaries
- Chiron Behring Vaccines Pvt Ltd